DK1124577T3 - Use of an enterobacterial OmpA protein for specific measurement for antigen-presenting cells - Google Patents

Use of an enterobacterial OmpA protein for specific measurement for antigen-presenting cells

Info

Publication number
DK1124577T3
DK1124577T3 DK99971719T DK99971719T DK1124577T3 DK 1124577 T3 DK1124577 T3 DK 1124577T3 DK 99971719 T DK99971719 T DK 99971719T DK 99971719 T DK99971719 T DK 99971719T DK 1124577 T3 DK1124577 T3 DK 1124577T3
Authority
DK
Denmark
Prior art keywords
antigen
protein
presenting cells
enterobacterial
ompa
Prior art date
Application number
DK99971719T
Other languages
Danish (da)
Inventor
Jean-Yves Bonnefoy
Sybille Lecoanet
Jean-Pierre Aubry
Pascale Jeannin
Thierry Baussant
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of DK1124577T3 publication Critical patent/DK1124577T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention concerns the use of an enterobacterium protein OmpA, preferably Klebsiella pneumoniae P40 protein, for specific targeting of a biologically active substance associated therewith towards antigen-presenting cells, in particular human dendritic cells. The invention also concerns the use of the OmpA protein for preparing a pharmaceutical composition for preventing and/or treating diseases, in particular cancers related to a tumour-associated antigen, autoimmune diseases or infectious diseases.
DK99971719T 1998-11-06 1999-11-08 Use of an enterobacterial OmpA protein for specific measurement for antigen-presenting cells DK1124577T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9814007A FR2785542B1 (en) 1998-11-06 1998-11-06 USE OF AN ENTEROMACTERY OmpA PROTEIN FOR THE SPECIFIC TARGETING OF A BIOLOGICALLY ACTIVE SUBSTANCE THAT IS ASSOCIATED WITH CELLS PRESENTING ANTIGENS SUCH AS HUMAN DENDRITIC CELLS
PCT/FR1999/002734 WO2000027432A1 (en) 1998-11-06 1999-11-08 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS

Publications (1)

Publication Number Publication Date
DK1124577T3 true DK1124577T3 (en) 2003-12-08

Family

ID=9532467

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99971719T DK1124577T3 (en) 1998-11-06 1999-11-08 Use of an enterobacterial OmpA protein for specific measurement for antigen-presenting cells

Country Status (14)

Country Link
EP (1) EP1124577B1 (en)
JP (1) JP2002529428A (en)
CN (1) CN1181890C (en)
AT (1) ATE247978T1 (en)
AU (1) AU764205B2 (en)
BR (1) BR9915071A (en)
CA (1) CA2350183A1 (en)
DE (1) DE69910809T2 (en)
DK (1) DK1124577T3 (en)
ES (1) ES2205946T3 (en)
FR (1) FR2785542B1 (en)
PT (1) PT1124577E (en)
WO (1) WO2000027432A1 (en)
ZA (1) ZA200103478B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790960B1 (en) * 1999-03-15 2002-10-31 Pf Medicament USE OF BACTERIAL MEMBRANE FRACTIONS WITH IMMUNOSTIMULANT ACTIVITY IN THE TREATMENT OF CANCERS, THEIR PREPARATION METHODS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2790959B1 (en) * 1999-03-15 2003-06-27 Pf Medicament USE OF BACTERIAL MEMBRANARY FRACTIONS WITH ADJUVANT EFFECT, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
AU6786600A (en) * 1999-08-20 2001-03-19 General Hospital Corporation, The Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
FR2803302B1 (en) * 2000-01-04 2004-12-10 Pf Medicament PROCESS FOR THE PREPARATION OF A SOLUBLE POLYPEPTIDE BY AQUEOUS SOLVENT IN THE ABSENCE OF DETERGENT
FR2809014A1 (en) * 2000-05-16 2001-11-23 Pf Medicament Use of an enterobacterium OmpA protein for prophylactic and therapeutic treatment of viral, bacterial, fungal and parasitic infections
FR2822071B1 (en) * 2001-03-15 2005-07-01 Pf Medicament USE OF A MEMBRANE FRACTION OF GRAM NEGATIVE BACTERIA TO INDUCE THE MATURATION OF DENDRITIC CELLS
EP2377883A1 (en) * 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
CN102286106B (en) * 2011-07-11 2013-05-01 中国人民解放军军事医学科学院微生物流行病研究所 Sandwich outer membrane protein display vector and escherichia coli vaccine prepared by applying same
KR20170011221A (en) * 2015-07-22 2017-02-02 이화여자대학교 산학협력단 Vaccine for preventing Klebsiella related disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726472B1 (en) * 1994-11-07 1997-01-31 Pf Medicament CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
FR2748476B1 (en) * 1996-05-07 1998-08-14 Pf Medicament IMMUNOGENIC COMPLEX, ITS USE, ITS PREPARATION METHOD AND VACCINE CONTAINING THE SAME

Also Published As

Publication number Publication date
FR2785542B1 (en) 2001-02-09
CN1181890C (en) 2004-12-29
EP1124577A1 (en) 2001-08-22
AU1164100A (en) 2000-05-29
CA2350183A1 (en) 2000-05-18
DE69910809T2 (en) 2004-06-17
EP1124577B1 (en) 2003-08-27
DE69910809D1 (en) 2003-10-02
JP2002529428A (en) 2002-09-10
ES2205946T3 (en) 2004-05-01
WO2000027432A1 (en) 2000-05-18
FR2785542A1 (en) 2000-05-12
CN1326360A (en) 2001-12-12
PT1124577E (en) 2004-01-30
BR9915071A (en) 2001-07-17
ZA200103478B (en) 2002-02-12
AU764205B2 (en) 2003-08-14
ATE247978T1 (en) 2003-09-15

Similar Documents

Publication Publication Date Title
FI962154A (en) Composition for the in vivo preparation of therapeutic products
DE69835201D1 (en) Neoglycoproteine
DE69835692D1 (en) LOADED LIPIDS AND THEIR USE
FR2727689B1 (en)
BR0014652A (en) Manufacture of therapeutic agent-polyglutamate conjugates
DK0839026T3 (en) Micellar polyether block copolymer compositions for targeting biological agents
NO962791L (en) Preparations containing nucleic acids, their preparation and use
ATE216590T1 (en) DRUG FORMULATIONS FOR IL-12
DK0749317T3 (en) Therapeutic applications of dimeric products of bactericidal / permeability enhancing protein
MY131095A (en) Polyethylene protein conjugates.
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
ATE232396T1 (en) OXIDATED THYMOSINE BETA 4
BR9801652A (en) Resorcinyl-triazines
DK1124577T3 (en) Use of an enterobacterial OmpA protein for specific measurement for antigen-presenting cells
MXPA03003704A (en) Kahalalide f formulation.
ATE371031T1 (en) HERPES SIMPLEX VIRUS EXPRESSING THE INTERLEUKIN-12 GENE AND ITS USE IN THE TREATMENT OF CANCER
ATE223221T1 (en) SOLUBLE MEDICINAL COMPOSITIONS CONTAINING 2-CHLORO-2'-DEOXYADENOSINE
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
YU58600A (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-(beta-l-ribofuranosyl)-1h-benzimidazole
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ATE232738T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COLOSTRUM AND THEIR USE
PT1150716E (en) PHARMACEUTICAL COMPOSITION OF HYDROBICALLY MODIFIED HEDGEHOG PROTEINS AND THEIR USE
PT980379E (en) CHEMICAL OLIGONUCLEOTIDES AND THEIR USE
GB9718415D0 (en) Formulation
UA26246C2 (en) COHTRACEPTIVE COMBINE PREPARATION